Studies about a radiosensitizer that is clinically usable
Project/Area Number |
24591845
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Radiation science
|
Research Institution | Sapporo Medical University |
Principal Investigator |
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | 放射線治療 / 子宮頚部癌 / DNA修復 / PARP阻害剤 / ノギテカン / 放射線増感剤 / DNA2重鎖切断 / 相同組換え修復 |
Outline of Final Research Achievements |
An inhibitor of Poly (ADP-ribose) polymerase-1 (PARP-1), Olaparib enhanced sensitivity to radiation and Camptothecin (CPT) at low concentrations and after relatively short exposure times such as 2 h. The radiosensitizing effect of olaprib was not dependent on the p53 status of tumor cells. These characteristics could be advantageous for clinical radiotherapy since tumor cells may be exposed to low concentrations of olaparib and/or may have different levels of p53 mutation. The combination of olaparib and CPT had a stronger radiosensitizing effect, indicating that combining a PARP inihibitor with a topoiomerase I inhibitor could be promising for clinical radiosensitization.
|
Report
(4 results)
Research Products
(4 results)
-
[Journal Article] Relation between Ku80 and microRNA-99a expression and late rectal bleeding after radiotherapy.2015
Author(s)
Someya M, Yamamoto H, Nojima M, Hori M, Tateoka K, Nakata K, Takagi M, Saitoh M, Hirokawa N, Tokino T, Sakata K
-
Journal Title
Radiotherapy and Oncology
Volume: in press
Issue: 2
Pages: 235-239
DOI
Related Report
Peer Reviewed
-
-
-